Phaseline

Companies › Guangzhou Henovcom Bioscience

Guangzhou Henovcom Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HNC364 Injectable Suspension
Rasagiline pro-drug; monoamine oxidase B (MAO-B) inhibitor
MAOBPhase 1Parkinson's Disease (PD)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06798519HNC364 Injectable SuspensionPhase 1Parkinson's Disease (PD)NeurologyDec 2026

Targets

MAOB (1)

Companies with the same targets

Corium Innovations

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.